Repligen Corporation (NASDAQ:RGEN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Repligen Corporation (NASDAQ:RGEN) have been assigned an average rating of “Moderate Buy” from the eighteen ratings firms that are covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have issued a strong buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $168.57.

Several equities analysts have issued reports on RGEN shares. Benchmark raised Repligen from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a research note on Tuesday, July 7th. Zacks Research downgraded shares of Repligen from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 28th. Wells Fargo & Company increased their target price on shares of Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a research note on Thursday, July 30th. UBS Group reaffirmed a “buy” rating on shares of Repligen in a research note on Tuesday, September 29th. Finally, Evercore restated an “outperform” rating and issued a $160.00 target price on shares of Repligen in a research note on Monday, July 6th.

Repligen Stock Up 4.3%

Shares of NASDAQ RGEN opened at $189.50 on Tuesday. The company has a market capitalization of $10.70 billion, a P/E ratio of 259.59, a price-to-earnings-growth ratio of 3.32 and a beta of 1.08. Repligen has a 52-week low of $100.99 and a 52-week high of $198.87. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. The company’s 50 day moving average price is $171.55 and its 200-day moving average price is $142.00.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.09. The company had revenue of $204.13 million during the quarter, compared to analysts’ expectations of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. Repligen’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Equities analysts forecast that Repligen will post 2.06 earnings per share for the current year.

Institutional Trading of Repligen

Hedge funds and other institutional investors have recently bought and sold shares of the business. United Capital Financial Advisors LLC acquired a new stake in shares of Repligen in the 2nd quarter worth about $380,756,000. Wasatch Advisors LP increased its holdings in Repligen by 27.9% during the 2nd quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock worth $216,974,000 after purchasing an additional 346,720 shares in the last quarter. Maverick Capital Ltd. purchased a new stake in shares of Repligen in the first quarter worth approximately $178,946,000. Conestoga Capital Advisors LLC raised its stake in shares of Repligen by 3.8% in the first quarter. Conestoga Capital Advisors LLC now owns 1,097,783 shares of the biotechnology company’s stock worth $129,341,000 after purchasing an additional 39,808 shares during the last quarter. Finally, Fred Alger Management LLC lifted its holdings in shares of Repligen by 154.3% in the fourth quarter. Fred Alger Management LLC now owns 911,527 shares of the biotechnology company’s stock valued at $149,363,000 after purchasing an additional 553,105 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to produce biological drugs, including monoclonal antibodies, recombinant proteins, vaccines and cell and gene therapies. Its products are used throughout the manufacturing process, from laboratory and process development through commercial-scale production.

The company’s portfolio includes chromatography products and protein A ligands and resins, filtration and fluid-management systems, single-use technologies, process analytics and other consumables and equipment.